Innate Pharma SA
IPHA2.080USD
-0.070-3.26%
Horário de mercado （ET）Cotações atrasadas em 15 min
174.33MValor de mercado
--P/L TTM
Mais detalhes de Innate Pharma SA Empresa
Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.
Informações da empresa
Código da empresaIPHA
Nome da EmpresaInnate Pharma SA
Data de listagemOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Número de funcionários- -
Tipo de títulosDepository Receipt
Fim do ano fiscalOct 31
Endereço117 avenue de Luminy
CidadeMARSEILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísFrance
Código postal13009
Telefone33430303030
Sitehttps://www.innate-pharma.com/
Código da empresaIPHA
Data de listagemOct 31, 2006
CEOMr. Jonathan Elliot Dickinson
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Mr. Olivier Martinez
Mr. Olivier Martinez
Member of the Supervisory Board, Representative of Bpifrance Participations
Member of the Supervisory Board, Representative of Bpifrance Participations
--
--
Ms. Claire De Saint-blanquat
Ms. Claire De Saint-blanquat
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
Vice President - Legal and Corporate Affairs, Secretary of the Supervisory Board, Member of the Leadership Team
--
--
Dr. Sally Bennett
Dr. Sally Bennett
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ms. Veronique Chabernaud, M.D.
Ms. Veronique Chabernaud, M.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Prof. Eric Vivier, Ph.D.
Prof. Eric Vivier, Ph.D.
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
Senior Vice President, Chief Scientific Officer, Member of the Leadership Team
--
--
Mr. Nicola Beltraminelli
Mr. Nicola Beltraminelli
Vice President, Chief Development Officer, Member of the Leadership Team
Vice President, Chief Development Officer, Member of the Leadership Team
--
--
Mr. Frederic Lombard
Mr. Frederic Lombard
Chief Financial Officer, Member of the Leadership Team
Chief Financial Officer, Member of the Leadership Team
--
--
Mr. Gilles Brisson
Mr. Gilles Brisson
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mr. Henry Wheeler
Mr. Henry Wheeler
Vice President - Investor Relations and Communications, Member of the Leadership Team
Vice President - Investor Relations and Communications, Member of the Leadership Team
--
--
Ms. Odile Belzunce
Ms. Odile Belzunce
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
Vice President - Compliance, IT and Portfolio Management, Member of the Leadership Team
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.02%
Other
99.84%
Investidores
Investidores
Proporção
AllianceBernstein L.P.
0.07%
Morgan Stanley & Co. International Plc
0.05%
Citadel Advisors LLC
0.03%
Millennium Management LLC
0.02%
Other
99.84%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
0.07%
Research Firm
0.05%
Hedge Fund
0.04%
Investment Advisor
0.01%
Other
99.83%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
17
157.41K
0.17%
-54.22K
2025Q1
22
261.37K
0.29%
-22.81K
2024Q4
23
278.64K
0.34%
-188.16K
2024Q3
25
406.53K
0.50%
-579.77K
2024Q2
27
405.72K
0.50%
-529.94K
2024Q1
29
344.92K
0.22%
-517.69K
2023Q4
32
202.70K
0.25%
-1.13M
2023Q3
36
377.53K
0.47%
-1.02M
2023Q2
36
293.58K
0.36%
-1.21M
2023Q1
33
404.31K
0.50%
-1.20M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
AllianceBernstein L.P.
60.75K
0.07%
+36.48K
+150.33%
Jun 30, 2024
Morgan Stanley & Co. International Plc
43.52K
0.05%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.27K
0.03%
+12.41K
+104.73%
Mar 31, 2025
Millennium Management LLC
15.33K
0.02%
+15.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
9.00K
0.01%
+5.49K
+156.44%
Mar 31, 2025
GAMMA Investing LLC
2.23K
0%
+2.23K
--
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
675.00
0%
--
--
Mar 31, 2025
Barclays Bank PLC
307.00
0%
--
--
Mar 31, 2025
Optiver Holding B.V.
101.00
0%
--
--
Mar 31, 2025
Tower Research Capital LLC
3.00
0%
+3.00
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ActivePassive International Equity ETF
0%
DFA Dimensional Intl Sustainability Core 1 ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
ActivePassive International Equity ETF
Proporção0%
DFA Dimensional Intl Sustainability Core 1 ETF
Proporção0%
DFA Dimensional International Core Equity 2 ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
